<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Bristol Myers Squibb & Co (NYSE: BMY) announced three-year data from the CheckMate -743 trial demonstrating a durable survival benefit with first-line treatment with Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemo in unresectable malignant pleural mesothelioma (MPM). Among patients treated with Opdivo plus Yervoy, 23% were alive at three years, compared to 15% treated with chemotherapy.
...read full article on Benzinga
